Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

e rates of 30% in this population of patients would represent a significant advance in the treatment of aggressive NHL and commented that that while numerically higher, the overall incidence of cardiac events were lower than expected in this patient group with substantial prior doxorubicin exposure reflected by no significant change in ejection fraction from baseline to end of treatment.

"This data demonstrates that pixantrone can induce durable complete remissions not only in patients previously treated with standard front-line doxorubicin, but even in patients who received an anthracycline as part of a salvage regimen. Resistance to rituximab was not associated with resistance to pixantrone. In patients with high cumulative prior doxorubicin exposure, the frequency of severe cardiac toxicity following up to six cycles of additional pixantrone was lower than would be expected based on historical comparisons to studies of doxorubicin," said James A. Bianco, M.D., Chief Executive Officer of CTI. "We are pleased with these results as they underscore the potential for pixantrone in this difficult to treat patient population for whom few options exist."

About the PIX301 EXTEND Trial

The PIX 301 EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal phase III EXTEND (PIX 301) trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu)
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  Neuralstem, Inc. (NYSE MKT: CUR) today reported ... principal investigator, presented updated Phase I data from its ... the treatment of amyotrophic lateral sclerosis (ALS or ... diabetes special medical symposium in Bucharest, Romania ... Therapeutic Advances in Stem Cell Therapy," Dr. Feldman outlined ...
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/20/2013)... -- With herbal medicines relied upon by consumers worldwide, ... Convention (USP) will provide freely available public standards to ... in these products. Today, USP proposes the first 23 ... Medicines Compendium ( HMC ) for comment by ... . HMC will provide standards for herbal ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
... Formation in ... Animals, Hearts, SUNRISE, ... of myoblasts modified to express,stromal derived factor-1(alpha) protein (SDF-1) into the ... were recently,presented at two scientific meetings -- the International Society for,Magnetic ...
... Enrollment Program Speeds Oncology Patient Accrual, ... Research Management,Organization (RMO), has contracted with five ... management services for their,clinical trials using the ... the following disease indications: follicular Non-Hodgkin,s,Lymphoma, Metastatic ...
Cached Medicine Technology:Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2
(Date:5/20/2013)... York (PRWEB) May 20, 2013 The nationwide ... study has found that magnetic resonance imaging (MRI) can be ... of whether or not patients are experiencing symptoms. According ... Journal of Bone & Joint Surgery, MRI detected synovitis (tissue ... patients suffering symptoms due to mechanical causes, the detection rate ...
(Date:5/20/2013)... A child whose mother lived near heavy traffic while ... respiratory infection before the age of 3, a new ... 1,300 pairs of mothers and infants from eastern Massachusetts. ... first trimester of pregnancy at some point between 1999 ... lived within 100 meters (about 110 yards) from a ...
(Date:5/20/2013)... transforms the sweet flavor of orange juice into something ... phenomenon in colorful, animated detail check the ... Bytesize Science video series at http://www.BytesizeScience.com ... explains that the mainstay ingredients in toothpaste include a ... When you brush your teeth, SLS produces the foamy ...
(Date:5/20/2013)... Join Seva Foundation in celebrating its 35th Anniversary with ... Fine Arts Theater in San Francisco, featuring: Snatam ... with host Wavy Gravy. All proceeds will benefit Seva Foundation’s ... seats are $40 & $55, VIP tickets are $150 and ... row seat at the show. Tickets are available through ...
(Date:5/20/2013)... May 20, 2013 Cliff Lake Dental Care is ... accommodate patient schedules when visiting the dentist office . The ... and life schedule. , Here are the new office hours: Mondays- ... Wednesday – 8 a.m. to 1 p.m. and 2-5 p.m., Thursdays ... the office will be open to take appointments only. Cliff Lake ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Cliff Lake Dental Care Announces Office Hours Change 2
... someday get a personalized menu of foods to eat during ... new research at Washington University// School of Medicine in St. ... a way to discover how genes and diet interact to ... know they are pregnant, the development of the fetus' organs ...
... that Maoris carry a "warrior" gene which make them ... terming such claims// as dangerous and inflammatory. ... Environmental Science and Research, Dr Rod Lea and his ... oxidase, often referred to as the warrior gene, which ...
... centre employees between the ages of 19 to 31 years ... insulin malfunction.// ,The Delhi Diabetes Research Centre had ... explained that the epidemic of diabetes has for a very ... that there is now an increasing trend where in younger ...
... mothers who took the anti-miscarriage drug diethylstilbestrol at the time ... to a new study published in the August issue of ... DES daughters over age 40 had 1.9 times the risk ... the drug. ,They also found that the relative ...
... Indian worker in Bahrain died, days before he was to ... ,A free visa worker, Muthanna Poshanna, 46, died following ... according to a report in the Gulf Daily News newspaper. ... that they were waiting for word from Poshanna's family in ...
... got the Oman government's permission to carry out surgeries ... the group's new centre in the Omani capital Muscat. ... the green signal to start our operation theatres, Intensive ... report in the Times of Oman newspaper quoted V.T. ...
Cached Medicine News:Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Warrior Gene Claims Slammed by Maori 2Health News:Warrior Gene Claims Slammed by Maori 3Health News:Studies Find That Call Centre Employees Could Be More Prone to Diabetes 2Health News:"DES Daughters" Have High Risk Of Breast Cancer 2Health News:"DES Daughters" Have High Risk Of Breast Cancer 3
Maddox Rod, short handle (12cm)...
Graham Field 10' Reversed Snellen Eye Chart....
... PacScan 300AP is a portable, ... provides easy-to-use touch screen operation. ... frequency, low noise probes and ... capture immediately upon application of ...
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
Medicine Products: